Quick answer : Ketamine is not an established treatment for grief itself or an FDA-approved treatment for Prolonged Grief Disorder. However, some people experiencing persistent grief also develop depression, PTSD, severe anxiety, or other symptoms for which ketamine may be considered.
For carefully selected patients, ketamine may create a temporary period of increased psychological flexibility that can support therapeutic work. Grief-focused psychotherapy remains an important part of treatment when grief has become persistent and disabling.
Grief is supposed to move. Not on a schedule, not cleanly, and not without setbacks, but over time the acute anguish of loss usually begins to change. Most people gradually find a way to carry the loss while continuing to engage with life.
For some people, that doesn’t happen. The grief remains intense and disabling. Thoughts of the person who died may dominate the day. Returning to relationships, work, interests, or imagining a future can feel nearly impossible.
When severe grief persists for at least 12 months after a death in adults, causes significant distress or impairment, and exceeds what would be expected within the person’s cultural, social, or religious context, it may meet criteria for Prolonged Grief Disorder (PGD). American Psychiatric Association
Ketamine is not an established treatment for PGD itself. But persistent grief can coexist with depression, PTSD, anxiety, sleep disturbance, and other symptoms. In carefully selected patients, that raises an important question: Could ketamine help with some of the symptoms surrounding grief and make therapeutic work more accessible?
Grief can be devastating without being a psychiatric disorder. For most people, its intensity changes over time. There may still be painful anniversaries, unexpected waves of sadness, and periods when the loss feels newly present.
Prolonged Grief Disorder is different. The grief remains intense and persistent enough to significantly interfere with daily functioning. Symptoms can include intense longing or preoccupation with the person who died, difficulty accepting the death, emotional pain or numbness, loneliness, avoidance of reminders, difficulty re-engaging with life, and a sense that life has lost meaning. American Psychiatric Association
Depression and PTSD can also occur alongside prolonged grief, but they are not the same condition. Identifying what is actually driving a person’s symptoms matters because treatment should be directed toward the problems that are present.
Some people can recognize that they have become stuck but still cannot change the pattern on their own.
Persistent rumination may keep bringing the person back to the circumstances of the death. Painful memories can feel just as immediate months later. Everyday activities may also lose their meaning.
At this point, treatment may focus on helping the person regain enough psychological flexibility to process the loss.
That does not mean forgetting the person who died. It does not mean moving on in the sense of leaving the relationship behind. Instead, treatment can help someone carry the loss while gradually reconnecting with life.
Ketamine does not erase grief, diminish the importance of the person who died, or remove the need to process a loss.
It is also important to be clear about the evidence: ketamine is not FDA-approved for grief or Prolonged Grief Disorder, and research specifically studying ketamine as a treatment for PGD remains limited.
Where ketamine may become relevant is when grief occurs alongside conditions such as treatment-resistant depression or PTSD, or when severe depressive and trauma-related symptoms are making therapeutic work difficult.
Ketamine can produce rapid antidepressant effects in some patients and has been studied for its effects on neuroplasticity and rigid patterns of thought and emotion. Clinically, this may create a temporary period in which some patients feel better able to engage with difficult emotions or psychotherapy.
That is different from saying ketamine “treats grief.” At Seaside Ketamine, we evaluate the entire clinical picture and determine whether ketamine, psychotherapy, another treatment, or a combination makes the most sense.
For some patients, particularly when grief is intertwined with trauma, depression, or PTSD symptoms, ketamine-assisted psychotherapy (KAP) may be considered as part of a broader treatment plan.
Examples can include:
Sudden death
Violent loss
Loss by suicide
Witnessing a death
Other traumatic circumstances surrounding a loss
Ketamine-Assisted Psychotherapy (KAP) combines the effects of ketamine with structured therapeutic support.
During KAP, the altered state produced by ketamine can help some patients approach memories or emotions that normally feel overwhelming. Patients may find that they can think about the person they lost from a different perspective or access parts of the loss they have struggled to process.
This does not make the work easy. Instead, it may make difficult therapeutic work more accessible.
Integration after KAP sessions also matters. Patients need time and support to process what surfaces during treatment and incorporate those experiences into their ongoing grief work.
We coordinate with grief-trained therapists in the San Diego and Newport Beach areas for patients who need additional therapeutic structure.
Ketamine for grief may be appropriate for patients who:
Have experienced intense, impairing grief for one year or longer with little sense of movement
Meet criteria for Prolonged Grief Disorder
Have significant depressive or PTSD symptoms alongside their grief
Have tried grief-focused therapy and found it helpful but not sufficient
Feel that therapy has reached a point where they cannot make further progress
Do not have acute suicidal risk that requires a higher level of care first
A thorough evaluation can help determine whether ketamine makes sense as part of a broader treatment plan.
The goal is not to make grief disappear. Instead, treatment aims to create enough psychological flexibility to begin processing the loss while continuing to carry the connection and meaning that remain.
No. Ketamine is not FDA-approved for grief or Prolonged Grief Disorder, and it should not be presented as an established treatment for grief itself.
Ketamine may become relevant when a person experiencing persistent grief also has treatment-resistant depression, PTSD, or other symptoms for which ketamine may be clinically appropriate.
The distinction matters. At Seaside Ketamine, treatment is based on the patient’s complete clinical picture rather than assuming that grief itself requires medication.
Losing someone to suicide can involve grief alongside trauma, guilt, unanswered questions, depression, anxiety, and other complex emotions. Whether ketamine-assisted psychotherapy is appropriate depends on the individual rather than the circumstances of the death alone.
A careful evaluation should determine which symptoms are present, their severity, current suicide risk, previous treatment, and whether grief-focused or trauma-focused psychotherapy should be central to treatment.
When KAP is appropriate, we believe it should be integrated with skilled therapeutic support rather than viewed as a replacement for grief therapy.
There is no standard waiting period after a loss that automatically determines whether ketamine is appropriate. Acute grief can be profoundly painful without being abnormal or requiring medical treatment.
In adults, Prolonged Grief Disorder cannot be diagnosed until at least 12 months after the death. However, depression, PTSD, severe anxiety, suicidal thoughts, or other psychiatric conditions can occur earlier and may require treatment in their own right. American Psychiatric Association
The decision to consider ketamine should therefore be based on the person’s symptoms, diagnosis, level of impairment, safety, treatment history, and overall clinical picture rather than simply the amount of time that has passed.
No. Ketamine is not FDA-approved for grief or Prolonged Grief Disorder. Its use in this context would be off-label and should be considered only after an individualized medical and psychiatric evaluation.
Evidence-based psychotherapy remains an important treatment for Prolonged Grief Disorder. Ketamine may be considered when clinically appropriate for co-occurring conditions such as treatment-resistant depression or significant trauma-related symptoms.
Prolonged Grief Disorder is a recognized mental health condition in which intense grief persists and significantly interferes with daily life. In adults, DSM-5-TR requires that the death occurred at least 12 months earlier.
Symptoms may include intense longing or preoccupation with the person who died, difficulty accepting the death, emotional pain or numbness, loneliness, avoidance, difficulty re-engaging with life, and a sense that life has lost meaning. Diagnosis also considers the person’s cultural, social, and religious context.
Psychotherapy specifically addressing prolonged grief has the strongest established evidence. Approaches may incorporate cognitive-behavioral strategies, processing the circumstances of the death, reducing avoidance, rebuilding social connection, and gradually re-engaging with meaningful activities and relationships. American Psychiatric Association
Medication may sometimes be used to treat co-occurring conditions such as depression, but there is currently no medication established specifically for treating Prolonged Grief Disorder itself.
